Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.52+0.03 (+2.01%)
Close on Nov 12, 2026Market cap $6.80MP/E –Yield –
Enveric Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Enveric Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$8.57M. For fiscal 2025 it was -$8.57M. The highest annual figure on record is -$31.24K in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.57M | – |
| FY2024 | Dec 31, 2024 | -$9.29M | – |
| FY2023 | Dec 31, 2023 | -$16.10M | – |
| FY2022 | Dec 31, 2022 | -$27.09M | – |
| FY2021 | Dec 31, 2021 | -$63.97M | – |
| FY2020 | Dec 31, 2020 | -$5.50M | – |
| FY2019 | Dec 31, 2019 | -$31.24K | – |
| FY2018 | Dec 31, 2018 | -$4.24M | – |
| FY2017 | Dec 31, 2017 | -$7.68M | – |
| FY2016 | Dec 31, 2016 | -$4.02M | – |
| FY2015 | Dec 31, 2015 | -$627.77K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.83M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.48M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.09M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.81M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.30M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$50.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.34M | -5127.4% |
| Q2 FY2021 | Jun 30, 2021 | -$3.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.05M | -292.6% |
| Q3 FY2020 | Sep 30, 2020 | $66.50K | – |
| Q2 FY2020 | Jun 30, 2020 | -$233.65K | – |
| Q1 FY2020 | Mar 31, 2020 | -$277.08K | – |
| Q4 FY2019 | Dec 31, 2019 | $2.62M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.00M | -114.9% |
| Q2 FY2019 | Jun 30, 2019 | -$913.87K | – |
| Q1 FY2019 | Mar 31, 2019 | -$737.35K | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.16M | – |
| Q3 FY2018 | Sep 30, 2018 | $6.74M | – |
| Q2 FY2018 | Jun 30, 2018 | -$270.21K | – |
| Q1 FY2018 | Mar 31, 2018 | -$546.06K | -1032.6% |
| Q4 FY2017 | Dec 31, 2017 | -$2.33M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.13M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.68M | – |
| Q1 FY2017 | Mar 31, 2017 | $58.55K | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.53M | – |
| Q3 FY2016 | Sep 30, 2016 | -$782.31K | – |
See a number that looks wrong?